Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Oncology Research Group
With
University Hospital of Crete
Treating patients with primary resistance to the most active multi-agent combination remains a challenging clinical problem. The reported data demonstrated that addition of ERBITUX may reverse IRINOTECAN resistance. Further data support the feasibility of the combination of two monoclonal antibodies (AVASTIN+ERBITUX) with IRINOTECAN with better responses compared to historical controls (ERBITUX±IRINOTECAN). As such, a phase II study was designed to evaluate the efficacy of the combination of AVASTIN plus ERBITUX plus IRINOTECAN as second line treatment in patients progressing while on treatment with FOLFIRI AVASTIN or XELIRI AVASTIN
Age
18–72
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed locally advanced or metastatic colorectal cancer.
Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)
ECOG performance status ≤ 2
Age 18 - 72 years
Patients with de novo refractory disease (progression of disease as best response at 1st line therapy with FOLFOX/Avastin)
Adequate liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 4 UNL, ALP ≤ 2.5 UNL),renal (Creatinine ≤ 1.5 UNL) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function
Patients must be able to understand the nature of this study
Written informed consent
You may not be if
History of serious cardiac disease (unstable angina, congestive heart failure, uncontrolled cardiac arrhythmias).
History of myocardial infarction or stroke within 6 months.
